



## Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

November 11, 2020

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3<sup>rd</sup> Annual Evercore ISI HealthCONx Conference.

### Stifel 2020 Virtual Health Conference

Date: Tuesday, November 17, 2020  
Time: 2:00 PM Eastern Time  
Format: Presentation

A live audio webcast of the presentation will be available in the Investors section on the Company's website at [www.cidara.com](http://www.cidara.com).

### 3<sup>rd</sup> Annual Evercore ISI HealthCONx Conference

Date: Wednesday, December 2, 2020  
Time: 11:20 AM Eastern Time  
Format: Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need

### About Cidara Therapeutics

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit [www.cidara.com](http://www.cidara.com).

### INVESTOR CONTACT:

Brian Ritchie  
LifeSci Advisors  
(212) 915-2578  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

### MEDIA CONTACT:

Karen O'Shea, Ph.D.  
LifeSci Communications  
(929) 469-3860  
[koshea@lifescicomms.com](mailto:koshea@lifescicomms.com)



Source: Cidara Therapeutics, Inc.